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Abstract
Background: WISDOM (Women Informed to Screen Depending on Measures of Risk) is a randomized trial to assess whether
personalized breast cancer screening—where women are screened biannually, annually, biennially, or not at all depending
on risk and age—can prevent as many advanced (stage IIB or higher) cancers as annual screening in women ages 40–74 years
across 5 years of trial time. The short study time in combination with design choices of not requiring study entry and exit
mammograms for all participants may introduce different sources of bias in favor of either the personalized or the annual
arm.
Methods: We designed a simulation model and performed 5000 virtual WISDOM trials to assess potential biases. Each virtual
trial simulated 65 000 randomly assigned participants who were each assigned a risk stratum and a time to stage of at least
IIB cancer sampled from an exponential distribution with the hazard rate based on the risk stratum. Results from the virtual
trials were used to evaluate two candidate analysis strategies with respect to susceptibility for introducing bias: 1) difference
between arms in total number of events over total trial time, and 2) difference in number of events within complete
screening cycles.
Results: Based on the simulations, about 86 stage IIB or higher cancers will be detected within the trial and the total exposure
time will be about 74 000 years in each arm. Potential ascertainment bias is introduced at study entry and exit. Analysis
strategy 1 works better for the nonscreened stratum, whereas method 2 is considerably more unbiased for the strata of
women screened biennially or every 6 months.
Conclusion: Combining the two candidate analysis approaches gives a reasonably unbiased analysis based on the
simulations and is the method we will use for the primary analysis in WISDOM. Publishing the WISDOM analysis approach
provides transparency and can aid the design and analysis of other individualized screening trials.
Annual mammograms for women over the age of 40 years have
been a key US strategy to reduce breast cancer mortality for
30 years. However, consensus on key aspects of mammography
screening, such as the age to begin screening, frequency of
screening, and the age to stop screening, have not been reach-
ed, and screening guidelines from professional organizations
differ (1–5).
Breast cancer risk models incorporating family history of
breast disease, endocrine exposures, breast density, and genetic
variants are now available (6–9). Armed with this better under-
standing of breast cancer risk, personalized screening—which
tailors screening recommendations, including the starting
age, stopping age, frequency, and modality of screening to an
individualized risk estimate—has been proposed as an
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alternative to the current “one-size-fits-all” guideline-based
approach (10–12).
The WISDOM (Women Informed to Screen Depending on
Measures of Risk) trial is a multicenter, randomized trial com-
paring personalized screening to annual screening in women
ages 40–74 years, initially opening in the Athena Breast Health
Network in California and the Midwest (13,14). There are two
co-primary study objectives. The first is to test whether person-
alized screening is safe, as measured by noninferiority in the
rate of advanced (stage IIB or higher) cancers. The second is to
test whether personalized screening is less morbid, as mea-
sured by a reduction in the number of breast biopsies.
Because this screening study has the short-term endpoint of
advanced cancers rather than the long-term survival endpoint
of mortality, particular care must be taken to avoid biased com-
parisons between the randomly assigned arms that arise from
assessing the women according to different schedules. In this
article, we describe the known sources of bias in the compari-
son of the two randomly assigned arms in the WISDOM trial.
We use a simulation study to evaluate the extent of the bias
and analytic approaches to reducing the bias. This ultimately
informs the structure of the WISDOM primary analyses. Our
aim is to provide transparency in our analysis methods of the
trial,and to share the tradeoffs made between trial design
choices and the potential bias. Moreover, as precision medicine
advances, more personalized screening trials will be designed
and conducted, and our experiences from designing WISDOM
should be useful to others.
Methods
WISDOM Design
WISDOM follows a preference-tolerant design (Figure 1) that
encourages women to be randomly assigned but also allows
self-assignment for those with strong personal preference for
either annual or risk-based screening [see eg, Weinstein et al.
(17) for a similar design]. For women in the personalized screen-
ing arm, individualized risk assessment is used to inform
screening frequency and modality [see Shieh et al. (13) for
details]. Women’s predicted risk is translated into one of four
different screening recommendations (Table 1) (13). Annual
mammogram will thus be compared to a mixture of recommen-
dations with different screening intervals. WISDOM is expected
to enroll 100 000 women (65 000 into the randomly assigned co-
hort). The trial time until the first analysis of the primary end-
points is 5.5 years.
Potential Sources for Bias
Study Entry
WISDOM does not require a study entry mammogram. Upon en-
rolling in the trial and receiving a screening recommendation,
each woman’s next future mammogram will be scheduled to be
consistent with her assigned screening frequency based on the
date of her most recent mammogram (Figure 2). Women who
enter the trial and are randomly assigned to the personalized
arm and receive a “no screening” recommendation will not re-
ceive an on-study mammogram unless, during the trial, they
meet a threshold for risk that would trigger screening. As a re-
sult of not requiring a study entry mammogram, some women
will enter the trial with a prevalent cancer. It should be noted,
however, that even if a study entry mammogram was used,
some women would still enter the study with a prevalent can-
cer because the sensitivity of mammograms is not 100%. The
prevalent cancers can introduce bias in the comparison be-
tween the study arms because there is a delay from when par-
ticipants enter the study to the time when they are screened in
accordance with their assigned screening schedule. This delay
could be overall longer in the personalized arm compared with
the annual arm, resulting in fewer events or longer times to
event. However, the actual extent and direction of this bias
depends on how prevalent cancers are handled in the analysis
(Box 1).
The rationale for not requiring a study entry mammogram is
that a key purpose of the trial is to avoid mammograms in the
lower risk groups. The goal of the study is to evaluate the initia-
tion of mammographic screening depending on risk. Adding a
study mammogram at entry changes the trial intervention to be
an initial mammogram followed by a recommended frequency
based on risk. In essence, we sacrifice some internal study va-
lidity for greater generalizability, which we consider a reason-
able design trade-off given the aims and pragmatic nature of
the trial.
Study Exit
WISDOM will not require a study exit mammogram in general.
The exception is women in the personalized arm who received
a “no screening” recommendation who will receive an exit
mammogram if they have been enrolled in the trial for at least 2
years. Because of the short trial duration, the observed rate of
cancers in this group will be assessed to determine if the rate of
cancers truly is low or if we observed a low rate because cancers
simply were not detected due to lack of screening. The exit mam-
mogram is thus required for this group to avoid verification bias,
which otherwise potentially could bias against the annual arm.
The lack of exit mammogram introduces a period of time be-
tween last on-study screen and study exit; on average, more
time will pass from the last within-study mammogram to the
end of the study for women who are screened less frequently
compared with women who are screened more frequently
(Box 1). Depending on how the trial is analyzed, this may intro-
duce bias in comparisons between the two arms.
Figure 1. Trial design overview. Women ages 40–74 years with no prior diagnosis
of breast cancer or history of bilateral mastectomy are eligible to join the trial.
For women who are either randomly assigned to or self-select personalized
screening, individualized risk assessment is used to inform screening frequency
and modality based on demographical and clinical risk factors using the Breast
Cancer Surveillance Consortium risk model (15,16), a polygenic risk score repre-
senting the cumulative effects of genetic variants (96 single nucleotide polymor-
phisms selected based on genome-wide significance in at least one racial or
ethnic group: Caucasians, East Asians, Hispanic/Latinos, African Americans)
(7,8), and moderate- and high-penetrance germline mutations (BRCA1, BRCA2,
TP53, STK11, PTEN, CDH1, ATM, PALB2, and CHEK2) (9).
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Candidate Analyses
The primary analysis will be based on the randomly assigned
cohort only. To have sufficient power, the primary analysis of
the safety endpoint will be based on a difference in the risk of
stage IIB or higher cancers between the two arms (18). The non-
inferiority margin is 0.05% absolute difference between the ran-
domly assigned arms. Therefore, the null hypothesis is that
personalized screening increases the risk for stage IIB or higher
cancers by at least 0.05%.
Below we describe the candidate approaches to analyzing
the results with respect to the primary efficacy endpoint.
Total Trial Time
The simplest analysis approach is to compare the number of
stage IIB cancers diagnosed in each arm throughout the entire
trial duration. In this approach, exposure time is counted from
the date of study entry to the date of stage IIB cancer detection
or date of study exit. We quantify the risk for stage IIB cancers
in each arm as a hazard rate or the number of events within
this exposure time. The advantage of this approach is that it is
transparent, and all stage IIB events, all exposure times, and all
randomly assigned women can be included in the analysis.
However, this approach does not make any attempt to address
the biases introduced at study entry and exit.
Time Within Complete Screening Cycles
For this approach, we try to control the potential bias at study
exit by counting events and exposure time only within com-
plete screening cycles. Exposure time is counted from the date
of study entry to the date of stage IIB cancer detection or last
completed screening cycle. Among women in the personalized
arm assigned to no screening, there is no screening cycle.
Therefore, to consider complete screening cycles among these
women, we include only those women who receive a study exit
mammogram and consider their screening cycle as the date
from study entry to the date of exit mammogram.
For the personalized arm, there will be more exposure time
within complete screening cycles for women with shorter
screening intervals than for women with longer intervals,
because, as an example, three whole annual cycles (¼ 3 years of
exposure time) fit in 3.5 years of follow-up whereas only one
whole biennial screening cycle (¼ 2 years of exposure time) fits
into the same time period. Because women undergoing
6 months or annual screening are a higher risk population, the
difference in exposure time needs to be corrected for in the
analysis by weighting the results within each stratum against
the inverse of the total exposure time in the stratum.
Time within complete screening cycles analysis option can
be extended to also address the biased introduced at study en-
try by excluding prevalent cancers from the analysis in both
arms. This option is analytically equivalent to giving all women
a study entry mammogram.
Simulation Methods
We used simulation to quantify bias and to understand the per-
formance of the candidates for the primary analysis. We simu-
late 65 000 virtual women in the trial. The 65 000 virtual women
are accrued within 3.5 years. Accrual rates are 5000, 25 000,
20 000, and 15 000 total women in the first 6 months of accrual
and then each year of accrual respectively. Women are equally
randomly assigned to annual or personalized screening.
Independent of randomly assigned arm, women are assigned a
risk stratum. We assigned risk stratum randomly according to a
multinomial distribution where there is a 28.9%, 40.4%, 28.2%,
and 2.5% probability of being in the lowest, average, elevated,
and highest risk strata, respectively. Annual hazards for the risk
strata were 0.0198%, 0.0414%, 0.0774%, and 0.2808% for women
from the lowest to highest risk group, respectively. The propor-
tion of women in each risk stratum and the corresponding an-
nual hazard rates were estimated by applying the Breast Cancer
Surveillance Consortium risk model and simulated polygenic
risk score (assuming independence between the polygenic risk
Table 1. WISDOM risk stratification and screening recommendations (13)
Risk Highest risk Elevated risk Average risk Lowest risk
Criteria/ threshold BRCA1/2, TP53, PTEN,
STK11, CDH1, ATM,
PALB2, or CHEK2 muta-
tion carrier
Women ages 40–49 y with
extremely dense breasts
Women ages 50–74 y Women ages 40–49 y with a
<1.3% 5-year risk of de-
veloping breast cancer
or or or
Women with a 6% 5-year
risk (risk of an average
BRCA carrier)
Women at a 1% 5-year
risk of developing
Estrogen Receptor breast
cancer based on suscepti-
bility Single Nucleotide
Polymorphisms
Women aged 40–49 y with a
1.3% 5-year risk (risk of
an average 50-year-old
woman)
or or
Women with a history of
mantle radiation
Women in top 2.5th percen-
tile of risk by 1-year age
category
Screening
recommendation
Annual mammogramþ
Magnetic Resonance
Imaging (MRI)
Annual mammogram* Biennial mammogram† No screening until age 50 y
*If individual does not meet criteria for annual mammogram þMRI.
†If individual does not meet criteria for annual mammogram or annual mammogram þ MRI. The risk predictions are based on the Breast Cancer Surveillance
Consortium risk prediction model together with a polygenic risk score.
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and other risk factors) to data collected within the Athena
Breast Health Network.
We then employ a simple natural history model of breast
cancer. First, we randomly assign women to have a prevalent
stage IIB cancer at randomization according to Bernoulli trials
with an .05% probability. Women who do not have a prevalent
stage IIB cancer at randomization are assigned a time to
mammogram-detectable stage IIB breast cancer. Time to
mammogram-detectable stage IIB cancer is simulated for
each woman according to an exponential distribution with
the hazard rate depending on risk strata. Sojourn times are
then simulated from an exponential distribution such that the
median sojourn time is 18 months. The time to clinically de-
tectable stage IIB cancer for each woman is then the sum of
her time to mammographically detected cancer and her so-
journ time.
Each virtual woman is then assigned a first planned screen-
ing time according to her screening recommendation based on
the randomization assignment and risk strata. However, we
also allow noncompliance to the planned screening time in the
form of a delay beyond the planned time. For each planned
screening, a noncompliance time is simulated from a truncated
normal distribution with a mean (SD) of 0 (4.5) months. This dis-
tribution is consistent with 55% of women having their mam-
mogram within 3 months of the scheduled date and 87% having
their mammogram within 6 months of the scheduled date
(19,20). The actual screening time is then planned mammogram
time plus any noncompliance time. Subsequent screenings are
then planned to occur according to her recommended schedule
relative to the actual screening time, not the planned screening
time, and continue to incorporate noncompliance as described.
For example, a woman enrolled in the first year of the trial and
assigned to annual screening will have planned mammograms
1, 2, and 3 years after her enrollment. Due to noncompliance,
her first mammogram may occur at 1 year and 2 months. The
BOX 1. Examples of bias introduced at study entry and exit
To illustrate bias introduced at study entry (A) and exit (B),
we use an example woman of average risk (Figure 2). She is
randomly assigned to either the annual arm or to the per-
sonalized arm, where she will be screened biennially be-
cause of her average risk. The same types of biases occur
also for women with very high or very low risk, who are dif-
ferentially screened in the annual and the personalized arm.
A. Example of bias introduced by prevalent cancers at study
entry.
A woman of average breast cancer risk has a negative
mammogram at M-1. Then 18 months later she decides to
enroll in WISDOM. Between her negative mammogram at
M-1 and her enrollment in WISDOM, she has developed
undetected stage IIB breast cancer. If she is randomly
assigned to the annual arm, she will get a mammogram
right after enrollment (MA1 ) because her last mammogram
was more than 12 months ago. Her prevalent cancer will
then likely be diagnosed at MA1 . However, if she is randomly
assigned to the personalized arm, she will be scheduled for
biennial mammograms receive her first on-study mammo-
gram 6 months after enrollment (MP1), where her prevalent
cancer will be diagnosed (if it has not already been symp-
tomatically detected as an interval cancer prior to the
mammogram).
Analysis options:
1) The prevalent cancer is counted in the primary analysis
irrespective of whether the woman is randomly assigned
to the annual or the personalized arm. We then risk bias-
ing against the annual arm because the cancer is
detected more quickly in the annual arm due to the
shorter screening cycle.
2) The prevalent cancer is excluded from analysis in both arms.
This option is analytically equivalent to giving all women a
M-1 
M1P 
M1A
M1P
R 
Annual arm 
Personalized arm 
C
M2A M3AA 
M1A
M1P
M2A
M2P
R 
Annual arm 
Personalized arm 
C
C
M3A M4AB 
Time 
Figure 2. An example woman of average risk is randomly assigned to either
the annual arm or to the personalized arm. Black vertical lines indicate mam-
mograms (M). R denotes randomization (study entry). Red dashed line indi-
cates end-of-study. Red arrows indicate development of stage IIB or higher
breast cancer.
study-entry mammogram. This analysis would reflect an in-
tervention that is an initial mammogram followed by a rec-
ommended frequency based on risk rather than the actual
trial intervention. It is also difficult to determine whether the
cancer was stage IIB prevalent at the time of randomization
when detected after the time of randomization.
B. Example of bias introduced at study exit.
A woman of average breast cancer risk has enrolled in
WISDOM. She develops stage IIB cancer before the end of
the study. If she is in the annual arm, her cancer is
detected at MA4 . However, if she is in the personalized arm,
the cancer has a higher chance of remaining undiagnosed
until the end of the study, because she will not have an-
other on-study screen after she develops cancer and before
the end of the trial.
Analysis options:
1) Count exposure time until end of study. Bias is intro-
duced, because more exposure time is added without
disease verification if the woman is screened biennially
compared with annually.
2) Only counting exposure time within complete screening
cycles avoids introducing bias to the cost of not counting
all cancers and all exposure time within the trial.
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next mammogram would then be planned to occur at 2 years
and 2 months, but due to noncompliance may occur at 2 years
and 6 months, and so on.
The total trial time is 4.5 years. Most women in the trial will
not develop a stage IIB cancer during the trial. Women that do
not develop a stage IIB cancer during the trial are considered to
not have cancer, with their exposure time being from their entry
into the trial to the time of their last screen or the time of trial
end depending on the analysis.
For women who do develop a stage IIB cancer during the
trial, we compare her natural history to her screening schedule.
If a screening occurs between the mammogram-detectable and
clinically detectable times, the cancer is considered detected by
mammogram at the time of screening. Otherwise, if a cancer
becomes clinically detectable in the interval between screen-
ings, it is considered clinically detected at that time. The simu-
lations thus assumed 100% sensitivity of a mammogram. To
explore the impact of this assumption, we also performed simu-
lations with lower mammogram sensitivity: 93%, 96%, 76%, and
86% for the lowest to highest risk groups, respectively (different
sensitivities due to the fact that risk strata are differently asso-
ciated with BIRADS breast density categories). Table 2 summa-
rizes the parameters used for the simulations.
We simulated the WISDOM trial in the manner described
above 5000 times. We track the total number of events and total
exposure time in each strata and overall. Exposure time was
calculated for the total duration of the trial and among com-
plete screening cycles only, in accordance with the two candi-
date analyses. All 5000 trial simulations were performed under
the alternative hypothesis that personalized screening is equiv-
alent to annual.
Results
The main results from the simulations are summarized in
Tables 3 and 4. Based on our simulations, about 86 stage IIB and
higher cancers will be detected within the trial and the total expo-
sure time will be about 74 000 years in each arm. We can expect
approximately 33 prevalent and 53 incident stage IIB cancers, and
34 clinically and 52 screen-detected cancers. The total number of
mammograms in each arm will be around 42 570 and 26 780 in
the annual and personalized arm, respectively (Table 4).
Bias Due to Study Entry
To determine the bias created from the lack of an entry mammo-
gram, we can compare results from simulations when no women
receive an entry mammogram and when all women receive an
entry mammogram (Table 4, B and C). A study entry mammo-
gram to remove prevalent cancers from the study population
clearly results in an almost entirely unbiased trial (the risk differ-
ence between personalized and annual screening is very close to
0 in all risk strata; Table 4, C). However, lack of entry mammo-
grams only creates a relatively small bias for the risk strata that
are recommended screening in the personalized arm (Table 4, B).
Bias Due to Study Exit
To determine the bias created from the lack of exit mammogram,
we can compare results of the hazard as calculated with the total
trial time vs the complete screening cycles (Table 4, A and B).
Using total trial time creates bias in the high- and average-
risk strata. In the high-risk strata, the bias favors the annual
arm and in the average risk strata the bias favors the personal-
ized arm. The estimated probability that the risk difference for
high-risk women in the personalized arm compared with the
annual arm is smaller than 0 (P[R< 0]) is .56 for high-risk women
and .33 for average-risk women. There is no bias introduced for
the women with elevated risk, because these women are recom-
mended the same screening schema in both arms. The bias also
appears to be low in the stratum where there is no screening in
the personalized arm (P[R< 0] ¼ .52).
Limiting the analysis to complete screening cycles reduces
the bias between arms in the strata with high and average risk.
P(R< 0) is .49 for high-risk women and .46 for average-risk
women. Using our definition of a screening cycle for
nonscreened women increases bias using complete screening
cycles compared with total trial time (P[R< 0] ¼ .43 and P[R< 0] ¼
.52, respectively). The price for the reduced bias for the high- and
average-risk strata is increased variance. The exposure time
counted is decreased by about 25 000 person-years (34%) and
21 000 person-years (29%) in the personalized and the annual
arm, respectively, compared with using total trial time. The total
number of events is, however, reduced by only 10% and 7%, re-
spectively. Because not all events occurring within the trial are
counted towards the primary analysis, the confidence intervals
are slightly wider compared with using the total trial time.
Because analyzing complete screening cycles introduces less
bias than total trial time for high- and normal-risk women
whereas total trial time works better for nonscreened women, a
reasonable approach is to combine the analysis methods in a
hybrid approach where complete screening cycles are used for
the risk strata that are recommended screening in the personal-
ized arm and total trial time is used for the nonscreened
women. Doing that results in P(R< 0) ¼ .47 across all risk groups
Table 2. Summary of parameters and distributions used in
simulations
Parameter Distribution
Accrual rate Year 1: 5000
Year 2: 25 000
Year 3: 20 000
Year 4: 15 000
Randomization 1: 1
Proportion in each risk strata Low risk: 28.9
Average risk: 40.4%
Elevated risk: 28.2%
High risk: 2.5%
Annual hazard for mammogram
detected cancer
Low risk: 0.0198
Average risk: 0.0414
Elevated risk: 0.0774
High risk: 0.2808
Median time from mammogram to
clinically detectable cancer
18 months
Noncompliance time Normalþ (0, 4 months)
Mammographic sensitivity 100%
(Low risk: 93%
Average risk: 86%
Elevated risk: 76%
High risk: 86%
used in sensitivity analyses)
Percent with prevalent stage IIB 0.05%
Total trial time 4.5 y
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(compared with .51 if prevalent cancers are removed using a
study entry mammogram).
Lowering the mammogram sensitivity did not materially af-
fect the results of the simulations (data not shown).
Discussion
Analyses of WISDOM that are as unbiased as possible are crucial
for drawing correct conclusions from the trial. We used simula-
tions to evaluate two approaches to analyzing the WISDOM
trial: 1) total number of events over the total trial duration, and
2) number of events within complete screening cycles. It is evi-
dent from the simulation results that method 1 works better for
the nonscreened strata, whereas method 2 is considerably more
unbiased for the groups of women screened biennially or every
6 months. Combining the two approaches gives a reasonably
unbiased analysis approach based on the simulation results
and is the method we will use in WISDOM. The main purpose of
the simulations was to understand how WISDOM design
choices may create bias and how different analysis choices may
correct for some of that bias rather than in a detailed fashion
model the natural history of breast cancer, for example, the
CISNET consortium (21).
Nonetheless, as observed in the simulation results, unde-
tected stage IIB cancers in women enrolling in the trial (preva-
lent cancers) does create potential for bias. Informed by the
simulation results, we will therefore perform two sensitivity
analyses in WISDOM to address this issue. First, exclude can-
cers detected at first on-study screens. This mimics having a
study entry mammogram and provides higher internal validity
to the cost of excluding events from the analysis. Second, re-
peated random exclusion of potential excess cancers detected
at first screen compared with subsequent screens (where the
screening interval is controlled within the trial).
We have here focused on two potential analysis paths, but
many more are possible. For instance, the trial could be ana-
lyzed within a model-based time-to-event framework with cen-
soring at the date of a breast cancer diagnosis, loss to follow-up,
death, and either at the end of the study or at the time point of
Table 3. Number of stage IIB or higher cancers by mode of detection*
Prevalent cancers stage IIB or higher, no. Screen detected, no. Clinically detected, no. Total, no.
Risk group Personalized Annual Personalized Annual Personalized Annual Personalized Annual
Every 6 months 2.3 2.3 5.1 3.9 1.5 2.1 6.5 6.0
Annual 7.1 7.1 12.0 12.0 6.7 6.6 18.7 18.6
Biennial 5.4 5.4 5.0 9.2 7.1 5.1 12.1 14.3
No screening at this time 1.8 1.8 2.1 3.1 2.9 1.7 5.0 4.9
All risk groups 16.6 16.6 24.2 28.2 18.1 15.5 42.3 43.7
*The table shows number of expected stage IIB or higher cancers in the Women Informed to Screen Depending on Measures of Risk (WISDOM) trial, by mode of detec-
tion, risk strata, and analysis approach. The results are based on the simulation model and are averaged across 5000 simulations.
Table 4. Expected results from the WISDOM trial
Risk group
Cancer  stage IIB, no. Exposure time, y Hazard rate Mean risk difference
P(R < 0)*
Mammograms, no.
Personalized Annual Personalized Annual Personalized Annual
(95% confidence
interval) Personalized Annual
Total trial time
High 6.5 6.0 1851 1850 0.352 0.324 0.028 (0.393 to 0.343) .56 2035 1058
Elevated 18.7 18.6 20 950 20 948 0.089 0.089 0.000 (0.059 to 0.056) .50 11 997 12 000
Average 12.1 14.3 30 028 30 031 0.040 0.048 0.007 (0.026 to 0.040) .33 6978 17 206
Low 5.0 4.9 21 494 21 492 0.023 0.023 0.001 (0.028 to 0.028) .52 5776 12 311
Overall† 42.3 43.7 74 324 74 320 0.057 0.059 0.002 (0.023 to 0.026) .44 26 786 42 576
Time within complete screening cycles
High 6.4 5.6 1520 1320 0.419 0.424 0.005 (0.456 to 0.481) .49 2035 1058
Elevated 17.4 17.4 14 935 14 933 0.117 0.116 0.000 (0.080 to 0.076) .50 11 997 12 000
Average 9.4 13.3 15 649 21 405 0.060 0.062 0.003 (0.049 to 0.051) .46 6978 17 206
Low 4.5 4.5 16 798 15 320 0.027 0.029 0.003 (0.034 to 0.041) .43 5776 12 311
Overall† 37.6 40.8 48 901 52 978 0.077 0.077 0.000 (0.032 to 0.035) .45 26 786 42 576
Time within complete screening cycles with entry mammogram
High 4.3 3.7 1518 1322 0.281 0.282 0.000 (0.394 to 0.400) .49 2843 1868
Elevated 11.6 11.7 14 930 14 931 0.078 0.078 0.000 (0.062 to 0.061) .50 21 154 21 154
Average 6.5 9.0 15 649 21 401 0.042 0.042 0.000 (0.041 to 0.042) .50 20 102 30 327
Low 4.5 4.2 16 794 15 318 0.027 0.027 0.000 (0.030 to 0.033) .47 5776 21 707
Overall† 26.9 28.6 48 891 52 973 0.055 0.054 0.000 (0.027 to 0.027) .51 49 875 75 055
*The table shows the expected total number of stage IIB or higher cancers, total exposure time, and hazard rate in the Women Informed to Screen Depending on
Measures of Risk (WISDOM) trial, by study arm, risk strata, and analysis approach. Computed risk differences between the annual and personalized arm with 95% con-
fidence intervals are also shown. P(R<0) shows the estimated probability that the risk difference is less than 0. Deviations from .5 indicate bias (in favor of the annual
arm P[R<0] > .5 and vice versa if P[R<0] < .5). The results are based on the simulation model and are averaged across 5000 simulations.
†Overall results are weighted against the inverse of the total exposure time in each stratum.
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the last complete screening cycle. A difficulty with a time-to-
event analysis of WISDOM is that the relative hazards are not
proportional over trial time (22). Time-varying effects could
potentially be used to address this issue; however, it would re-
quire fitting a complex and less transparent model to limited
data.
This report discussed the analysis of WISDOM’s primary safety
endpoint. The same issues with potential bias introduced at study
entry and exit arise in the analysis of the primary efficacy endpoint
and the same approaches are applicable for the analysis.
Biases introduced at study entry and exit are more pro-
nounced in a comparably short screening trial like WISDOM.
However, the benefit of short studies using a relevant proxy
endpoint are that they minimize the chance of being obsolete
by the end of the trial and enable more rapid dissemination of
the results. Thus, it is important for the analytic tools to adjust
and support rapid knowledge turns and to keep pace with the
continuous advances in the field of risk prediction and breast
cancer screening.
Our goal was to provide the background needed to support
new designs for modern screening studies and to make the
analysis of WISDOM transparent, in particular because it is out-
side the standard screening trial framework of comparing
screening to no screening or of comparing different screening
modalities (22–25). As precision medicine advances, the atten-
tion to personalized screening is likely to increase, because it is
a potentially effective means to balance the benefit and harms
of screening. We hope that this report raises the awareness of
some possible pitfalls in the analysis and interpretation of per-
sonalized screening trials, which are likely to become more
common.
Funding
This work was supported by the Patient-Centered Outcomes
Research Institute and the Robert Wood Johnson Foundation.
The WISDOM Study is funded by the Patient-Centered
Outcomes Research Institute (PCS-1402-10749). The statistical
planning began during the pilot and planning phase, which
was funded by the Robert Wood Johnson Foundation.
Notes
Affiliations of authors: Department of Medical Epidemiology
and Biostatistics, Karolinska Intitutet, Stockholm, Sweden (ME);
Berry Consultants LLC, Austin, TX (KB); Department of Surgery,
University of California San Francisco, San Francisco, CA (CY,
ASF, LJE); Buck Institute for Research on Aging, Novato, CA (CY);
University of Central Florida College of Medicine, Orlando, FL
(JC); Confluence Stat, Orlando, FL (JC).
WISDOM is registered at ClinicalTrials.gov (NCT02620852).
References
1. Siu AL. Screening for breast cancer: U.S. Preventive Services Task Force rec-
ommendation statement. Ann Intern Med. 2016;164(4):279–296.
2. Wilt TJ, Harris RP, Qaseem A. Screening for cancer: advice for high-value care
from the American College of Physicians. Ann Intern Med. 2015;162(10):718.
3. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging:
recommendations from the society of breast imaging and the ACR on the use
of mammography, breast MRI, breast ultrasound, and other technologies for
the detection of clinically occult breast cancer. J AmColl Radiol. 2010;7(1):18–27.
4. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening—
viewpoint of the IARC working group. N Engl J Med. 2015;372(24):2353–2358.
5. Oeffinger KC, Fontham ETH, Etzioni R, et al. Breast cancer screening for
women at average risk. JAMA. 2015;314(15):1599.
6. Cintolo-Gonzalez JA, Braun D, Blackford AL, et al. Breast cancer risk models: a
comprehensive overview of existing models, validation, and clinical applica-
tions. Breast Cancer Res Treat. 2017;164(2):263–284.
7. Mavaddat N, Pharoah PDP, Michailidou K, et al. Prediction of breast cancer
risk based on profiling with common genetic variants. JNCI J Natl Cancer Inst.
2015;107(5):doi:10.1093/jnci/djv036.
8. Vachon CM, Pankratz VS, Scott CG, et al. The contributions of breast density
and common genetic variation to breast cancer risk. JNCI J Natl Cancer Inst.
2015;107(5):doi:10.1093/jnci/dju397.
9. Easton DF, Pharoah PDP, Antoniou AC, et al. Gene-panel sequencing and the
prediction of breast-cancer risk. N Engl J Med. 2015;372(23):2243–2257.
10. Pashayan N, Duffy SW, Chowdhury S, et al. Polygenic susceptibility to pros-
tate and breast cancer: implications for personalised screening. Br J Cancer.
2011;104(10):1656–1663.
11. Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ.
Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol.
2016;13(9):550–565.
12. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammog-
raphy by breast density and other risk factors for breast cancer: analysis of
health benefits and cost-effectiveness. Ann Intern Med. 2011;155(1):10.
13. Shieh Y, Eklund M, Madlensky L, et al. Breast cancer screening in the preci-
sion medicine era: risk-based screening in a population-based trial. J Natl
Cancer Inst. 2017;109(5):doi:10.1093/jnci/djw290.
14. Esserman LJ, WISDOM Study and Athena Investigators the WS and A. The
WISDOM Study: breaking the deadlock in the breast cancer screening debate.
NPJ Breast Cancer. 2017;3(34):doi:10.1038/s41523-017-0035-5.
15. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE,
Kerlikowske K. Using clinical factors and mammographic breast density to
estimate breast cancer risk: development and validation of a new predictive
model. Ann Intern Med. 2008;148(5):337.
16. Tice JA, Miglioretti DL, Li C-S, Vachon CM, Gard CC, Kerlikowske K. Breast
density and benign breast disease: risk assessment to identify women at
high risk of breast cancer. J Clin Oncol. 2015;33(28):3137–3143.
17. Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical versus nonsurgical ther-
apy for lumbar spinal stenosis. N Engl J Med. 2008;358(8):794–810.
18. Broglio KR, Connor JT, Berry SM. Combining risk difference and risk ratio in
noninferiority trials of safety. J Biopharm Stat. 2013;23(1):261–271.
19. Partin MR, CaseyPaal AL, Slater JS, Korn JE. Measuring mammography com-
pliance: lessons learned from a survival analysis of screening behavior.
7:681–687. http://cebp.aacrjournals.org/content/cebp/7/8/681.full.pdf.
Accessed November 2, 2017.
20. Boudreau DM, Luce CL, Ludman E, Bonomi AE, Fishman PA. Concordance of
population-based estimates of mammography screening. Prev Med. 2007;
45(4):262–266.
21. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant ther-
apy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–1792.
22. Prorok PC1, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colo-
rectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6):
273S–309S.
23. Schro¨der FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer
mortality in a randomized European study. N Engl J Med. 2009;360(13):
1320–1328.
24. Baker SG, Kramer BS, Prorok PC. Statistical issues in randomized trials of can-
cer screening. BMCMed Res Methodol. 2002;2:11.
25. Prorok PC, Marcus PM. Cancer screening trials: nuts and bolts. Semin Oncol.
2010;37(3):216–223.
M. Eklund et al. | 7 of 7
